P M Jacobi1, S Kanaji2, D Jakab1, A L Gehrand1, J M Johnsen3,4, S L Haberichter1,5. 1. Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA. 2. Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA. 3. Research Institute, BloodWorks Northwest, Seattle, WA, USA. 4. Department of Medicine, University of Washington, Seattle, WA, USA. 5. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
Essentials Reduced survival of von Willebrand factor (VWF) in plasma causes type 1C von Willebrand disease. Blood was collected from mouse strains by various methods and VWF propeptide and antigen assayed. VWF propeptide to antigen ratio identifies a reduced VWF survival phenotype in mice. This ratio validates the acceptability of murine blood samples for coagulation studies. SUMMARY: Background Reduced plasma survival of von Willebrand factor (VWF) is characteristic of patients with type 1C von Willebrand disease (VWD). These subjects can be identified by an increased steady-state ratio of plasma VWF propeptide (VWFpp) to VWF antigen (VWF:Ag). A similar phenotype occurs in mice with the Mvwf1 allele. Objectives To (i) determine if the VWFpp/VWF:Ag ratio can be used to identify a 'type 1C' phenotype in mice, (ii) determine the most reliable method for murine blood sampling, and (iii) identify the source of VWF released during problematic blood collection. Methods 'Platelet-VWF' and 'endothelial-VWF' mice were generated by bone marrow transplantation between C57BL/6J and VWF-/- mice. Several blood sampling methods were used and murine VWFpp and VWF:Ag levels determined. Plasma and platelet VWF:Ag and VWFpp, VWF multimers and VWF half-life were examined in mouse strains with and without Mvwf1. Results A single retro-orbital bleed and vena cava collection were found to be the optimal methods of blood collection. Problematic collection resulted in release of VWF from platelets and endothelium. The VWFpp/VWF:Ag ratio identified strains of mice with reduced VWF survival. Conclusion Assay of murine VWFpp and VWF:Ag has utility in determining the acceptability of murine blood samples for coagulation testing and in identification of a reduced VWF survival phenotype in mice.
Essentials Reduced survival of von Willebrand factor (VWF) in plasma causes type 1C von Willebrand disease. Blood was collected from mouse strains by various methods and VWFpropeptide and antigen assayed. VWFpropeptide to antigen ratio identifies a reduced VWF survival phenotype in mice. This ratio validates the acceptability of murine blood samples for coagulation studies. SUMMARY: Background Reduced plasma survival of von Willebrand factor (VWF) is characteristic of patients with type 1C von Willebrand disease (VWD). These subjects can be identified by an increased steady-state ratio of plasma VWFpropeptide (VWFpp) to VWF antigen (VWF:Ag). A similar phenotype occurs in mice with the Mvwf1 allele. Objectives To (i) determine if the VWFpp/VWF:Ag ratio can be used to identify a 'type 1C' phenotype in mice, (ii) determine the most reliable method for murine blood sampling, and (iii) identify the source of VWF released during problematic blood collection. Methods 'Platelet-VWF' and 'endothelial-VWF' mice were generated by bone marrow transplantation between C57BL/6J and VWF-/- mice. Several blood sampling methods were used and murine VWFpp and VWF:Ag levels determined. Plasma and platelet VWF:Ag and VWFpp, VWF multimers and VWF half-life were examined in mouse strains with and without Mvwf1. Results A single retro-orbital bleed and vena cava collection were found to be the optimal methods of blood collection. Problematic collection resulted in release of VWF from platelets and endothelium. The VWFpp/VWF:Ag ratio identified strains of mice with reduced VWF survival. Conclusion Assay of murine VWFpp and VWF:Ag has utility in determining the acceptability of murine blood samples for coagulation testing and in identification of a reduced VWF survival phenotype in mice.
Authors: Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter Journal: Blood Date: 2012-03-19 Impact factor: 22.113
Authors: Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol A Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap Journal: Blood Date: 2011-02-23 Impact factor: 22.113
Authors: A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom Journal: J Thromb Haemost Date: 2006-10-16 Impact factor: 5.824
Authors: W C Nichols; K A Cooney; K L Mohlke; J D Ballew; A Yang; M E Bruck; M Reddington; E K Novak; R T Swank; D Ginsburg Journal: Blood Date: 1994-06-01 Impact factor: 22.113
Authors: Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery Journal: Blood Date: 2008-03-14 Impact factor: 22.113
Authors: Yvonne V Sanders; Dafna Groeneveld; Karina Meijer; Karin Fijnvandraat; Marjon H Cnossen; Johanna G van der Bom; M Coppens; Joke de Meris; Britta A P Laros-van Gorkom; Eveline P Mauser-Bunschoten; Frank W G Leebeek; Jeroen Eikenboom Journal: Blood Date: 2015-02-11 Impact factor: 22.113
Authors: Jill M Johnsen; Gallia G Levy; Randal J Westrick; Priscilla K Tucker; David Ginsburg Journal: Mamm Genome Date: 2008-01-11 Impact factor: 2.957